New York Mets’ reliever Jenrry Mejia was suspended for the second time this season for 162 games by the Major League Baseball after being tested positive for performance-enhancing drugs.
This July 7 only Mejia returned after an 80-game-suspension for PED. But MLB declined to comment whether Mejia’s current positive test came before or after he was reinstated in the League from the initial suspension. Earlier, Mejia was suspended for intake of a PED called Stanozolol. This time, the magnitude of guilt is much higher, as he has been tested positive for taking anabolic steroids Stanozolol and Boldenone. Thus follows the quantum of punishment.
New York Mets’ general manager Sandy Alderson expressed his disbelief after the suspension was announced.
“Not surprisingly, there’s a tremendous amount of disappointment — I think to some extent anger, to some extent amazement — that this could happen so soon after a previous suspension was completed. And some sadness,” Alderson said. “This is having a tremendously adverse effect on a very promising major league career, and that’s a shame. But the rules are the rules. We support the rules. This is the consequence of making bad choices.”
The 25-year-old had played 7 1/3 scoreless innings since his return on July 12. Earlier, the reliever issued a statement after his first suspension was announced on April 11 clarifying that he had no idea how performance enhancing drugs intruded in his cells.
”I can honestly say I have no idea how a banned substance ended up in my system,” said Mejia.
Alderson said that by the time they were noticed by MLB about Mejia’s suspension, the Mets’ have completed the acquisition process of setup man Tyler Clippard from the Oakland Athletics.
“Our track in talking with Oakland about Tyler as well as other players was independent of this situation,” stated Alderson.